2월 25일에, Cyagen Biosciences Suzhou Inc.는 2억8500만 위안 (약 4,400 만 달러 상당)의 시리즈 B 파이낸싱을 완성했으며 이 투자는 GF증권(GF securities)가 전액 소유하고 있는 CMS Capital, GF Qianhe, GF Xinde 및 광화투자(Guanghua Investment)가 관리하는 펀드입니다.
Read More ›
At the end of 2019, an outbreak of the COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan - having brought a huge impact on the lives of the people in China.
Read More ›
Are you considering custom animal models to accelerate your next research project? Cyagen's Discount of the Decade Event can help you extend your research with big savings for multiple projects - the more animal models you order from any eligible service, the more you save!
Read More ›
Since the identification of the intermediate filament (IF), nestin, it has been used as a marker for Neural Stem Cells (NSCs) and commonly considered as a key component of the cytoskeleton.
Read More ›
Since the early 2000s, large-scale knockout consortia have been established with the goal of generating a complete resource of reporter-tagged null mutations in C57BL/6 mouse ES cells. Herein, we provide a brief introduction to the ‘knockout-first’
Read More ›
As CRISPR-based innovations begin to move into clinical testing and the dispute over core patents continues worldwide, CRISPR-Pro gene editing has been under increased scrutiny in both commercial and academic sectors.
Read More ›
Synaptic impairment is known to be a prerequisite to the cognitive deficiencies exhibited in Alzheimer's Disease (AD), so investigating the mechanisms which
Read More ›
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy
